COLCHICINE AFTER A CORONARY

A trial of colchicine (a gout treatment) for secondary prevention of complications after an acute coronary event (myocardial infarction) showed no differences between active treatment and placebo groups at one year. However, after two years, the group taking colchicine showed a reduction in death rates, stroke and acute coronary syndrome. This may be due to the modulating effects of colchicine on inflammation and plaque (fatty deposits in coronary arteries).